Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology company whose news flow reflects activity across medical discovery, diagnostics, drug delivery and interventional care. On this page, readers can follow company-issued updates and third-party coverage related to BD’s operations, product clearances, collaborations and corporate developments.
Recent BD news highlights regulatory milestones, such as U.S. FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System, a multi-modality breast biopsy platform designed to support early detection and diagnosis of breast disease. Other announcements showcase BD’s role in supporting the pharmaceutical supply chain, including investments to expand production of BD Neopak™ Glass Prefillable Syringes in the United States to help meet growing demand for biologic and GLP-1 drug delivery.
Investors and observers can also track BD’s clinical and surgical innovations, including milestones with Phasix™ Mesh for hernia prevention in Europe and progress in the PREVENT trial, as well as the European launch of the BD Surgiphor™ Surgical Wound Irrigation System. In diagnostics and research, BD reports collaborations with institutions such as the University of Pennsylvania’s Institute for Immunology and Immune Health, and product updates like new IVDR-certified VIASURE assays for the BD MAX™ System and expanded configurations of BD FACSDiscover™ A8 Cell Analyzers.
Corporate governance and financial communications feature in BD’s news as well, with items such as leadership appointments in investor relations and notices regarding annual shareholder meetings. This news feed offers a centralized view of BD’s product pipeline, strategic investments, partnerships and regulatory events, providing context for how the company positions itself within the medical technology landscape.
BD (Becton, Dickinson and Company) reported first fiscal quarter revenues of $5.315 billion, a 25.8% increase year-over-year, driven by $867 million from COVID-19 diagnostics. Diluted EPS rose to $3.35, up 285.1% from the previous year. The BD Medical segment saw revenues of $2.261 billion, while BD Life Sciences grew to $1.979 billion, reflecting significant COVID-19 contributions. BD expects fiscal 2021 revenue growth of 12% to 14% and adjusted EPS of $12.75 to $12.85, indicating robust financial momentum.
BD (Becton, Dickinson and Company) announced positive outcomes from the CLEAN3 trial, demonstrating that its vascular care solution significantly reduces peripheral intravenous catheter (PIVC) failures, showing rates of 34.8% versus 47.5% in the control group. The trial observed enhanced performance regarding antiseptics, with catheter colonization at 0.9% compared to 16.9%. Conducted at Poitiers University Hospital, France, the study involved around 1,000 patients, highlighting the benefits of BD’s integrated solution for improving patient safety and reducing hospital costs.
On January 26, 2021, BD (Becton, Dickinson and Company) announced that Tom Polen, current CEO, will also become chairman of the board effective April 28, 2021. He succeeds Vincent A. Forlenza, retiring after leading BD through significant transformations. Under Polen's leadership, BD expanded its role during the COVID-19 pandemic by enhancing diagnostic testing and manufacturing essential medical supplies. Polen, with over 20 years at BD, aims to drive the BD 2025 strategy focused on growth, simplification, and empowerment to improve global healthcare delivery.
The Board of Directors of BD (Becton, Dickinson and Company) has announced a quarterly dividend of $0.83 per share, payable on March 31, 2021, to shareholders on record as of March 10, 2021. This marks an annual dividend rate of $3.32 per share. BD is a leading global medical technology company focused on enhancing health care delivery and improving medical diagnostics through innovative solutions, impacting health outcomes globally.
BD (Becton, Dickinson and Company) has published a peer-reviewed study indicating that its antigen test may be more effective than PCR tests in identifying contagious COVID-19 patients. Analyzing 38 PCR-positive specimens, the antigen test showed 27 were indeed contagious, while 10 of the PCR results suggested non-infectious individuals. This suggests the BD Veritor™ Plus System could enhance public health responses during the pandemic. Published in Clinical Infectious Diseases on January 22, 2021, the study emphasizes the potential of antigen testing to contain COVID-19 spread effectively.
BD (Becton, Dickinson and Company) reported preliminary financial results for Q1 fiscal 2021, with revenues expected to be $5.3 billion, a 25.6% increase year-over-year. This growth was driven by strong demand for COVID-19 diagnostics, particularly the BD Veritor™ tests. The BD Life Sciences segment saw a 76.3% revenue increase, attributed to COVID-19 testing. The company expects to finalize its financial results by February 4, 2021, with updates anticipated during the J.P. Morgan Healthcare Conference on January 12, 2021.
BD (Becton, Dickinson and Company) will present at the 39th Annual J.P. Morgan Healthcare Conference via webcast on January 12, 2021, at 7:30 a.m. Eastern Time. Investors can access the live presentation on the company's corporate website, with a replay available until January 19, 2021. BD is a leading global medical technology company dedicated to enhancing health through innovative technologies and solutions. With 65,000 employees worldwide, BD focuses on advancing clinical therapy, improving diagnostic accuracy, and addressing global health challenges.
BD (Becton, Dickinson and Company) has received pandemic orders exceeding 1 billion injection devices, including needles and syringes, to assist with COVID-19 vaccination globally. Shipments of over 300 million devices have already begun, with remaining orders scheduled for delivery through 2021. The company is also investing $1.2 billion over four years to enhance manufacturing capacity for pre-fillable syringes. BD collaborates with various governments to ensure vaccination readiness and has supplied millions of diagnostic products for COVID-19 treatment.
BD (Becton, Dickinson and Company) (NYSE: BDX) announced successful results from a 52-subject clinical trial of the BD Libertas™ Wearable Injector, designed for subcutaneous delivery of biologics. The device effectively administered 5 mL of 8 cP injections with no severe adverse reactions, showcasing high patient acceptance. All participants expressed willingness to use the device if prescribed. This marks a significant advancement in drug delivery technology, especially for larger volume biologics, as BD aims to support pharmaceutical partners in developing innovative therapies.
BD (Becton, Dickinson and Company) plans to invest approximately $1.2 billion over four years to enhance its manufacturing capacity for pre-fillable syringes (PFS) and advanced drug delivery systems (ADDS) across six global locations, including a new facility in Europe expected to be operational by 2023. This investment aims to improve supply continuity and accommodate increased demand from pharmaceutical companies for injectable drugs. BD has already expanded its capacity by 350 million units since 2018, reinforcing its leadership in the market.